Skip to main content

Leukemia / Lymphoma Clinical Trials

 

St. Jude Clinical Trials

AML16: Epigenetic Priming in Patients with Acute Myeloid Leukemia

Phase II Trial of Epigenetic Priming in Patients with Newly Diagnosed Acute Myeloid Leukemia

Diseases Treated:

Acute myeloid leukemia (AML)

Eligibility:

  • Diagnosis of one of the following:
    • Acute myeloid leukemia (AML)
    • 5% to 20% marrow myeloblasts and evidence of a clonal de novo AML genetic abnormality
    • Myeloid sarcoma
    • High grade myelodysplastic syndrome (MDS) with greater than 5% blasts
    • Treatment-related myeloid neoplasms, including AML and MDS
  • 28 days to 21 years old
  • No prior therapy, except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine
  • Not pregnant
View Trial

CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)

CATCHAML: CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia

Diseases Treated:

Acute Myelogenous Leukemia

Eligibility:

 

*FDA requires initial participants to be at least 16 years old.

View Trial

HAP2HCT: Partially Matched Family Donor Bone Marrow Transplant in Children and Young Adults with High Risk Cancer

TCRαβ-depleted Progenitor Cell Graft with Additional Memory T-Cell DLI, plus Selected Use of Blinatumomab, in Naïve T-Cell depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Diseases Treated:

Eligibility:

For transplant recipient:

  • 21 years or younger
  • Does not have a suitable sibling donor or volunteer unrelated donor
  • Has a suitable single haplotype matched family member donor
  • Diagnosed with high risk hematologic malignancy
  • No prior allogeneic hematopoietic cell transplant
View Trial

HAPNK1: Blood and Marrow Transplant (BMT) for Children with Leukemia/Lymphoma

Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation with a TLI-Based Conditioning Regimen in Patients with Hematologic Malignancies

Diseases Treated:

Leukemia and lymphoma

Eligibility:

  • 21 years and younger
  • Does not have a suitable HLA-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate for conventional matched donor transplant due to refractory disease
  • Has a suitable single haplotype-matched family member donor
  • High-risk hematologic malignancy, including certain diagnoses of:
    • Acute lymphoblastic leukemia (ALL)
    • Acute myeloid leukemia (AML)
    • Chronic myelogenous leukemia (CML)
    • Myelodysplastic syndrome (MDS)
    • Hodgkin lymphoma
    • Non-Hodgkin lymphoma
View Trial

INOMRD: Inotuzumab Ozogamicin for Children with High-Risk B-Cell ALL

Inotuzumab Ozogamicin for Children with MRD Positive CD22+ Acute Lymphoblastic Leukemia

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

  • Younger than 22 years old
  • Diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) between 0.1 and 4.99% after prior chemotherapy, relapse or stem cell transplant
View Trial

REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma

Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

Diseases Treated:

Eligibility:

  • 21 years old and younger
  • Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
    • Acute lymphoblastic leukemia (ALL)
    • Acute myeloid leukemia
    • Myeloid sarcoma
    • Chronic myeloid leukemia (CML)
    • Juvenile myelomonocytic leukemia (JMML)
    • Myelodysplastic syndrome (MDS)
    • Non-Hodgkin lymphoma (NHL)
  • Has a family member who is a suitable stem cell donor
View Trial

SJBC3: Mature B-cell Lymphoma and Leukemia Study III

Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia

Diseases Treated:

Leukemia and lymphoma

Eligibility:

  • 21 years of age or younger
  • Newly diagnosed mature B-cell non-Hodgkin lymphoma and leukemia
  • No previous treatment (no more than 72 hours of steroids, one intrathecal chemotherapy treatment, and/or emergency radiation)
View Trial

SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia

A Phase I/II Study Evaluating CD19-Specific CAR Engineered Autologous T-Cells in Pediatric and Young Adult Patients with Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

 

 

View Trial

TINI: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL)

Diseases Treated:

Acute lymphoblastic leukemia (ALL)

Eligibility:

  • Newly diagnosed ALL
  • 1 year of age or younger at the time of diagnosis
  • Has not had any — or has had limited — prior therapy
  • Does not have mature B-cell ALL, acute myeloid leukemia (AML) or Down syndrome
View Trial

TOT17: Total Therapy for Children with Acute Lymphoblastic Leukemia and Lymphoma

Total Therapy Study 17 for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia and Lymphoma

Diseases Treated:

Leukemia and lymphoma

Eligibility:

  • Diagnosis of B-cell or T-cell acute lymphoblastic leukemia (ALL) or acute lymphoblastic lymphoma (LLy)
  • 1 to 18 years old
  • No prior therapy or limited prior therapy
View Trial

VENAML: Chemotherapy Combined with Venetoclax in Children with Refractory or Relapsed Acute Myeloid Leukemia

A Phase I and Expansion Cohort Study of Venetoclax in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia

Diseases Treated:

Acute myeloid leukemia (AML), acute undifferentiated leukemia, mixed phenotype acute leukemia

Eligibility:

  • Diagnosis of relapsed or refractory acute myeloid leukemia (AML), acute undifferentiated leukemia or mixed phenotype acute leukemia 
  • At least 2 years old and younger than 22 years old
  • Recovered from acute effects of prior therapy and no evidence of graft-versus-host disease (GVHD)
  • Adequate liver, kidney and heart functions
View Trial

Collaborative Clinical Trials

cHOD17: Risk-Adapted Therapy for Children and Young Adults with Hodgkin Lymphoma

Pediatric Classical Hodgkin Lymphoma Consortium Study

Diseases Treated:

Lymphoma

Eligibility:

  • Previously untreated CD30+ classical Hodgkin lymphoma
  • 21 years or younger at time of diagnosis (low-risk and intermediate-risk patients)
  • 25 years or younger (high-risk patients)
View Trial

PEPN1812 : Study of Flotetuzumab in Children with Relapsed or Refractory Acute Myeloid Leukemia

Phase I Trial of Flotetuzumab, a CD123 X CD3 Dual Affinity Re-Targeting (DART) Molecule, in Pediatric Patients with Relapsed/Refractory AML

Diseases Treated:

Acute Myeloid Leukemia (AML)

Eligibility:

  • Younger than 21 years of age
  • Diagnosed with recurrent or refractory acute myeloid leukemia (AML)
  • Weigh more than 17kg 
  • Fully recovered from the acute toxic effects of all prior anti-cancer therapy
View Trial

TINI: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL)

Diseases Treated:

Acute lymphoblastic leukemia (ALL)

Eligibility:

  • Newly diagnosed ALL
  • 1 year of age or younger at the time of diagnosis
  • Has not had any — or has had limited — prior therapy
  • Does not have mature B-cell ALL, acute myeloid leukemia (AML) or Down syndrome
View Trial